

MEETING ABSTRACTS

BRAIN EXPOSURE OF BIS-PYRIDINIUM OXIME KR-26256

Hyun Myung Lee¹, Sunjoo Ahn¹, Sung Hee Cho¹, Soo Bong Han¹, Hyejin Kim¹, Sang Ho Lee¹,
Gyeunghaeng Hur² and Young-Sik Jung¹

¹ Korea Research Institute of Chemical Technology, Daejeon 34114, South Korea

² Agency for Defense Development, Daejeon 34188, South Korea

A number of strategies through structural modification of pyridinium oximes have been developed to circumvent the Blood-Brain Barrier (BBB). Some of the attempted examples are (1) enhancement of lipophilicity by introduction of a fluorine atom into pyridinium ring, (2) facilitation of glucose transporters introduction of glucose moiety on the pyridinium nitrogen, (3) use of a prodrug by uncharged dihydropyridyl moiety, etc

One of the strategies that our group tried was the introduction of fluorine atoms into the heterocyclic ring of pyridinium oximes to increase their lipophilicity.¹ In our continuing effort towards the development of new oxime reactivators, we were interested in monoquaternary pyridinium oximes with *N*-alkyl side chains, because oximes with hydrophobic side chains may penetrate the BBB more easily than 2-PAM with an *N*-methyl side chain. We also investigated bis-pyridinium oximes with diethyl ether linker between two pyridine rings.

The synthesized pyridinium oximes were evaluated their inhibitory activities on AChE, as well as their potency to reactivate AChE inhibited by paraoxon organophosphorus agent. The plasma and brain disposition of oximes were evaluated in male ICR mice, and the oximes concentrations in the plasma and brain were measured by LC-MSMS analysis. Therefore, KR-26256 which is a bis-pyridinium oxime showed higher brain concentration as well as better brain/plasma ratio compared with HI-6.

References

1. "Reactivation Potency of Fluorinated Pyridinium Oximes for Acetylcholinesterases Inhibited by Paraoxon Organophosphorus Agent", Hee Chun Jeong, Nam Sook Kang, No-Joong Park, Eul Kyun Yum, Young-Sik Jung, *Bioorganic & Medicinal Chemistry Letters*, **2009**, 19, 1214–1217
2. Kamil Kuca, Daniel Jun, Tae-Hyuk Kim, Jiri Cabal, Young-Sik Jung, "In Vitro Evaluation of New Acetylcholinesterase Reactivators as Casual Antidotes against Tabun and Cyclosarin", *Bull. Korean Chem. Soc.* **2006**, 27, 395-398